Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
IceCure Medical Ltd is a medical device company focused on the development, manufacturing, and commercialization of minimally invasive cryoablation systems for the treatment of tumors. The company operates within the medical devices and interventional oncology industries, with a primary emphasis on breast cancer and benign breast tumors, while also addressing other oncological and non-oncological indications. IceCure’s technology is designed to destroy diseased tissue through controlled freezing, offering an alternative to traditional surgical procedures.
The company’s core product is the ProSense® Cryoablation System, which represents its primary revenue driver and strategic platform. IceCure primarily serves hospitals, outpatient clinics, and healthcare providers specializing in oncology, women’s health, and interventional radiology. Its competitive positioning is based on a combination of minimally invasive treatment, reduced recovery times, and potential cost efficiencies compared to surgery. IceCure was founded in 2006 and has evolved from a development-stage company into a commercial-stage medical device firm, culminating in its public listing on Nasdaq under the ticker ICCM.
Business Operations
IceCure generates revenue primarily through the sale of cryoablation systems, single-use disposable probes, and related services associated with the ProSense® Cryoablation System. Operations are structured around the development, regulatory approval, manufacturing oversight, and commercialization of its proprietary cryotherapy technology. The company maintains regulatory clearances in multiple jurisdictions, including the United States and Europe, which support its commercial activities.
The company operates through several subsidiaries, including IceCure Medical Inc. in the United States and IceCure Medical (Shanghai) Co., Ltd. in China, which support regional sales, marketing, and regulatory efforts. IceCure also works with third-party distributors and strategic partners in various international markets. Its technology portfolio centers on cryogen-based ablation systems, proprietary probes, and integrated software designed to provide precise temperature control and real-time monitoring during procedures.
Strategic Position & Investments
IceCure’s strategic direction is focused on expanding the clinical adoption of cryoablation as a standard-of-care alternative to surgery for early-stage breast cancer and other indications. Growth initiatives include pursuing expanded regulatory approvals, increasing physician education, and supporting clinical trials intended to broaden reimbursement coverage and guideline inclusion. The company has emphasized the importance of U.S. market penetration, particularly following regulatory clearances from the U.S. Food and Drug Administration (FDA).
Investment activity has centered on internal research and development rather than large-scale acquisitions. IceCure continues to invest in next-generation cryoablation technologies, additional clinical indications, and software enhancements. The company has also entered into distribution and commercialization agreements in Asia and Europe to accelerate market access. Data inconclusive based on available public sources regarding any material acquisitions beyond routine business development transactions.
Geographic Footprint
IceCure Medical is headquartered in Israel, with its principal executive offices and research activities located there. The company maintains an operational presence in North America, Europe, and Asia, reflecting its global commercialization strategy. The United States represents a key strategic market due to its large addressable patient population and reimbursement dynamics.
Internationally, IceCure operates through a combination of wholly owned subsidiaries and regional distribution partners. The company has established a direct presence in China through its local subsidiary to support regulatory activities and commercial expansion, while European market access is supported through CE-mark approvals and regional partners. This geographic diversification allows IceCure to balance regulatory, clinical, and commercial risks across multiple healthcare systems.
Leadership & Governance
IceCure Medical was founded by a group of entrepreneurs and medical technology professionals, with ongoing leadership continuity since its early stages. The company’s governance structure includes an experienced executive team and board overseeing strategy, regulatory compliance, and capital allocation. Leadership has consistently articulated a vision centered on transforming cancer care through minimally invasive, patient-centric technologies.
Key executives include:
- Eyal Shamir – Chief Executive Officer and Chairman of the Board
- Dr. Rony Shemesh – Chief Financial Officer
- Yaron Daniely – Vice President, Research & Development
- Shachar Daniel – Vice President, Operations
- Tamar Miller – Vice President, Clinical and Regulatory Affairs
The leadership team emphasizes disciplined clinical validation, regulatory rigor, and long-term value creation through technology differentiation and global market expansion.